Melanotan I (Afamelanotide): The Tanning Peptide That Actually Made It Through FDA Approval
There are two “Melanotan” peptides, and mixing them up could be a serious mistake. Melanotan I — now known by the pharmaceutical name afamelanotide — is the one with a genuine FDA-approved medical use, a rigorous clinical trial program, and a legitimate manufacturer. Melanotan II, a related but distinct compound widely sold on the gray market, has a very different (and considerably more concerning) story. This article is about Melanotan I specifically: the science, the approved use, and what the gray-market versions mean for everyone who isn’t an EPP patient.
Quick Answer: Melanotan I (afamelanotide) is a synthetic α-melanocyte-stimulating hormone (α-MSH) analog that stimulates melanin production in skin. It is FDA-approved (brand name Scenesse) specifically for adults with erythropoietic protoporphyria (EPP), a rare genetic light-sensitivity disorder. It is not approved for cosmetic tanning or general sun protection. Gray-market versions sold online lack pharmaceutical quality guarantees and are not legally authorized for human use outside EPP treatment.
What Is Melanotan I?
Melanotan I, chemically known as afamelanotide (previously [Nle4,D-Phe7]-α-MSH), is a synthetic analog of α-melanocyte-stimulating hormone (α-MSH). α-MSH is an endogenous 13-amino-acid neuropeptide derived from pro-opiomelanocortin (POMC) that binds to melanocortin receptors throughout the body.
The key modification in afamelanotide relative to native α-MSH involves substituting norleucine for methionine at position 4 and D-phenylalanine for L-phenylalanine at position 7. These substitutions dramatically increase both potency (due to better receptor binding) and metabolic stability (resistance to enzymatic degradation), extending the half-life from minutes (native α-MSH) to approximately 15 hours for afamelanotide — and much longer with the slow-release implant formulation (Clinuvel Pharmaceuticals’ Scenesse delivers sustained release over approximately 60 days).
The development of Melanotan I (and its analog Melanotan II) originated from research at the University of Arizona, where Dr. Mac Hadley and colleagues synthesized multiple α-MSH analogs in the 1980s searching for compounds that could tan skin without UV exposure — originally conceived as a potential skin cancer prevention approach.
The FDA-Approved Use: Erythropoietic Protoporphyria (EPP)
Afamelanotide received FDA approval in October 2019 under the brand name Scenesse, made by Clinuvel Pharmaceuticals, specifically for the indication of increasing pain-free light exposure time in adults with erythropoietic protoporphyria (EPP).
EPP is a rare inherited metabolic disorder caused by deficiency of ferrochelatase enzyme, leading to accumulation of protoporphyrin IX in red blood cells, plasma, and skin. Exposure to visible light causes accumulated protoporphyrin to generate reactive oxygen species in skin cells, leading to immediate and severe burning pain — not a sunburn sensation, but an acute, incapacitating pain response that can occur within minutes of sun exposure. This condition severely limits quality of life; patients describe being unable to spend time outdoors, attend outdoor events, or even sit near windows.
Afamelanotide works by pre-stimulating melanin production in skin before light exposure. The increased melanin acts as a broader-spectrum light filter, reducing the activation of accumulated protoporphyrin and the resulting phototoxic reaction.
The Clinical Trial Evidence
The pivotal Phase III trials (Langendonk et al., New England Journal of Medicine, 2015) enrolled patients with confirmed EPP in Europe and North America. In the landmark trial, afamelanotide significantly increased the time patients could spend outdoors in sunlight without pain — from a median of less than 1 hour per day without treatment to several hours with treatment. Patient-reported quality of life measures improved substantially.
The Scenesse product is delivered as a biodegradable subcutaneous implant (a small pellet inserted under the skin of the upper arm), not as an injection. The implant releases afamelanotide slowly over approximately two months.
This is a genuine FDA-approved drug for a real and debilitating condition. The clinical evidence is solid, the manufacturing standards are pharmaceutical-grade, and the benefit-risk ratio for EPP patients is clearly positive.
Melanocortin Receptors and Why They Matter
Understanding why Melanotan I and Melanotan II are different requires understanding the five melanocortin receptor subtypes (MC1R–MC5R):
- MC1R: Expressed in melanocytes; mediates skin pigmentation and melanin synthesis. Primary target for tanning effects.
- MC3R and MC4R: Expressed in the brain; involved in appetite regulation, energy homeostasis, and sexual function. MC4R activation by Melanotan II (but less so by Melanotan I) drives its appetite-suppressing and sexual side effects.
- MC2R: ACTH receptor in adrenal gland; regulates cortisol production.
- MC5R: Expressed in exocrine glands; roles in sebum production and other functions.
The critical distinction: Afamelanotide (Melanotan I) preferentially binds MC1R more selectively than Melanotan II, which is a more promiscuous melanocortin receptor agonist. This receptor selectivity is why afamelanotide does not share Melanotan II’s aphrodisiac effects or its more pronounced appetite-suppression — both of which arise from central MC3R/MC4R activation.
Melanotan II: The Gray-Market Version You Should Understand Separately
Melanotan II (MT-II) is a cyclic analog of α-MSH developed around the same time as Melanotan I. It has never received pharmaceutical approval anywhere in the world and is sold exclusively as a gray-market research chemical.
Melanotan II’s non-selective melanocortin receptor activation causes:
- More potent skin tanning (MC1R)
- Appetite suppression (MC4R)
- Sexual arousal/spontaneous erections (MC4R in spinal cord and brain)
- Nausea, facial flushing, and yawning (MC4R-related effects)
These CNS effects are why Melanotan II became popular in the gray market — but they also represent significant off-target pharmacology with unknown long-term consequences. Melanoma cases have been reported in association with gray-market melanocyte-stimulating peptide use, though causality is difficult to establish definitively. The concern is that supraphysiological MC1R stimulation could accelerate proliferation of dysplastic nevi or pre-existing melanoma cells.
This article is about Melanotan I specifically. MT-II is a different compound with different pharmacology and risk profile.
Gray-Market Melanotan I Products
Despite afamelanotide being an FDA-approved drug manufactured by Clinuvel under strict pharmaceutical standards, gray-market versions of “Melanotan I” are sold online by research peptide vendors.
The issues with these products:
- Quality and purity: Without pharmaceutical manufacturing standards, the identity, purity, and concentration of peptide products cannot be guaranteed. Peptide synthesis errors, degradation products, and contamination are real risks.
- Formulation: The Scenesse product uses a proprietary biodegradable implant formulation specifically designed for sustained delivery. Gray-market Melanotan I is typically lyophilized powder for reconstitution and subcutaneous injection — an entirely different pharmacokinetic profile.
- Legal status: Using afamelanotide outside of its FDA-approved indication (EPP) without a prescription is not legally authorized in the US.
- Safety monitoring: Legitimate Scenesse use involves physician oversight, monitoring for skin changes and other adverse effects, and implant removal capability. Self-injection without this oversight removes important safety nets.
Skin Pigmentation and Tanning Effects
For people without EPP interested in cosmetic tanning, the honest assessment is:
Melanotan I and Melanotan II do produce skin darkening through melanin stimulation. This effect is real and documented. However:
- The FDA did not approve afamelanotide for cosmetic tanning
- The safety profile for long-term cosmetic use has not been established
- Stimulating melanogenesis in people who have nevi (moles) or who have genetic risk factors for melanoma raises theoretical concerns about promoting melanocyte proliferation
- The gray-market products lack pharmaceutical quality assurance
- There are legitimate concerns about injection safety (site reactions, infection, incorrect dosing)
UV-based tanning and tanning beds have well-documented melanoma risk. Whether chemical melanogenesis via MC1R agonism shares similar risks is not definitively established, but the concern is scientifically credible enough to warrant caution.
Frequently Asked Questions
Is Melanotan I FDA-approved for tanning?
No. Afamelanotide (Scenesse/Melanotan I) is FDA-approved only for erythropoietic protoporphyria (EPP). It is not approved for cosmetic tanning. Using it for cosmetic tanning constitutes off-label use of a prescription pharmaceutical, or involves using an unapproved gray-market product.
What is the difference between Melanotan I and Melanotan II?
Melanotan I (afamelanotide) preferentially activates MC1R (skin pigmentation receptor) with more receptor selectivity. Melanotan II is a more potent but less selective melanocortin receptor agonist that also strongly activates MC3R and MC4R in the brain and spinal cord, producing aphrodisiac effects, appetite suppression, and more pronounced systemic side effects. Melanotan I has received FDA approval for EPP; Melanotan II has never received approval anywhere.
Can Melanotan I cause melanoma?
This is a genuine concern that is not fully resolved. MC1R is expressed on melanocytes, and some research suggests that MC1R variants are associated with melanoma risk. Chronic MC1R stimulation from exogenous agonists theoretically could promote melanocyte proliferation. There are anecdotal reports of rapidly changing nevi (moles) in gray-market Melanotan II users, though causality is not established. Anyone with a personal or family history of melanoma or many nevi should be particularly cautious.
How does Scenesse (afamelanotide) work as an implant?
The Scenesse implant is a small, biodegradable, slow-release pellet containing 16 mg of afamelanotide inserted subcutaneously in the upper arm by a healthcare provider. It releases afamelanotide over approximately 60 days, maintaining blood levels that continuously stimulate melanogenesis. This sustained-release approach is distinct from pulsatile injection dosing and is important for its EPP efficacy.
Can Melanotan I help with vitiligo?
MC1R stimulation logically might help with vitiligo (a condition of depigmented skin patches) by stimulating remaining melanocytes. There is very limited published research on this, including some small studies. Clinuvel has investigated afamelanotide for vitiligo in combination with phototherapy (the VITILUX studies), with some positive pilot data. This is not an approved use, and full-scale clinical trials would be needed to establish benefit and safety for vitiligo specifically.
Sources
- Langendonk, J.G., Balwani, M., Anderson, K.E., et al. (2015). Afamelanotide for erythropoietic protoporphyria. New England Journal of Medicine, 373(1), 48–59.
- Hadley, M.E., Dorr, R.T. (2006). Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides, 27(4), 921–930.
- U.S. Food and Drug Administration. (2019). FDA approves afamelanotide for erythropoietic protoporphyria. FDA News Release.
- Brzoska, T., Luger, T.A., Maaser, C., et al. (2008). Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory, and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine Reviews, 29(5), 581–602.
- Cone, R.D. (2006). Studies on the physiological functions of the melanocortin system. Endocrine Reviews, 27(7), 736–749.
- Clinuvel Pharmaceuticals Limited. (2022). Scenesse (afamelanotide) Prescribing Information. Clinuvel Pharmaceuticals.
Leave a Reply